Among cell cycle checkpoint kinase genes, we observed 1.5-fold enrichment for ATM mutation (alone, not in combination with any other gene of interest) in primary ER+/HER2− breast cancer relative to metastatic disease (P = 0.003) (Fig. 5B). This evidence concerns the gene ESR1 and breast carcinoma.